Stryker (SYK) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
23 Mar, 2026Executive summary
Definitive additional proxy materials have been filed in accordance with SEC regulations, indicating an upcoming shareholder meeting or vote.
No filing fee was required for this submission, as specified in the filing details.
Voting matters and shareholder proposals
The filing relates to proxy materials soliciting shareholder votes, as indicated by the Schedule 14A submission.
Shareholder rights and capital structure
The document references securities transactions and the potential for shareholder voting on such matters, though no specific transaction details are provided.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Stryker
- Q2 sales rose 9.4% and adjusted EPS climbed 17.9%, driven by strong recovery and volume growth.SYK
Q2 2026 - Full-year outlook remains strong, with robust recovery and innovation driving growth.SYK
Bank of America Global Healthcare Conference 2026 - Strong sales growth, innovation, and all proposals approved; outlook remains robust.SYK
AGM 2026 - Cyber incident pressured Q1 margins, but sales rose 2.6% and full-year guidance is reaffirmed.SYK
Q1 2026 - Double-digit sales and EPS growth in 2025, with robust 2026 outlook and margin expansion.SYK
Q4 2025 - Q3 net sales up 11.9% and adjusted EPS up 16.7%, with strong 2024 outlook.SYK
Q3 2024 - Growth driven by innovation, robotics, and portfolio shifts, with margin and global expansion in focus.SYK
Citi’s 2025 Medtech and Life Sciences Access Day - Raised 2025 outlook after double-digit organic growth and Inari acquisition, despite margin pressure.SYK
Q1 2025 - Double-digit organic growth, margin expansion, and strategic moves set up a strong 2025 outlook.SYK
Q4 2024